2016 ACVIM Forum Research Abstract Program

Five purpose-bred cats with unremarkable complete blood count, serum biochemistry and urinalyses were utilized. PK study: Each cat received 0.8 mg/kg subcutaneous (SQ) and intravenous (IV) dolasetron in a cross-over manner. Serum samples were obtained via jugular catheter at 0, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 36 and 48 hours after administration of dolasetron. Dolasetron and the active metabolite hydrodolasetron were measured using liquid chromatography/tandem mass spectrometry. Non-compartmental pharmacokinetic analysis was performed. PD study: Subcutaneous dolasetron (0.8 mg/kg or 1.0 mg/kg) or placebo was administered 30 minutes prior to intramuscular administration of 0.44 mg/kg xylazine in a randomized crossover manner. Number of emetic events, lip licks, time to onset of vomiting or visual nausea score were scored by a blinded observer.